ReviewFrontiers in immunology2019
Multiplicity of Mesenchymal Stromal Cells: Finding the Right Route to Therapy.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.Cell transplantationPooled it
- Responders vs. non-responders to mesenchymal stromal cells in knee osteoarthritis: Mechanistic correlates of donor cell and patient features.Stem cell reports · 2026Trial
- Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism-Endpoint Relationship.Reviews in cardiovascular medicine · 2026Review
- Three-dimensional (3D) culture-primed placental mesenchymal stem cells decrease cellular heterogeneity, significantly enhancing osteogenesis via improving mitochondrial function.Materials today. Bio · 2026Article
- Donor age and sex program MSC secretome signaling: a quadrant framework for precision therapy.Stem cell research & therapy · 2026Article
- Establishing protocols for the efficient expansion of canine and feline adipose tissue-derived mesenchymal stromal cells following cell isolation.BMC veterinary research · 2025Article
- Mechanism of mesenchymal stem cells in treating diabetic kidney disease.Stem cell research & therapy · 2025Review
- Extracellular vesicle bioactivity and potential for clinical development are determined by mesenchymal stromal cell clonal subtype.Stem cell research & therapy · 2025Article
- Organoid-based tissue engineering for advanced tissue repair and reconstruction.Materials today. Bio · 2025Review
- Long-term in vivo monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging.EBioMedicine · 2025Article
- Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing.NPJ Regenerative medicine · 2025Article
- The therapeutic potential of different mesenchymal stem cells and their derived exosomes in metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2025Review
- Extracellular matrices of stromal cell subtypes regulate phenotype and contribute to the stromal microenvironment in vivo.Stem cell research & therapy · 2024Article
- Human umbilical cord-derived mesenchymal stem cells attenuate hepatic stellate cells activation and liver fibrosis.Molecular biology reports · 2024Article
- Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.International journal of molecular sciences · 2024Review
- Exosomes: A New Hope for Angiogenesis-Mediated Bone Regeneration.International journal of molecular sciences · 2024Review
- The potency of mesenchymal stem/stromal cells: does donor sex matter?Stem cell research & therapy · 2024Review
- Extracellular Vesicles from Human Induced Pluripotent Stem Cells Exhibit a Unique MicroRNA and CircRNA Signature.International journal of biological sciences · 2024Article
- Attitudes Towards Standardization of Mesenchymal Stromal Cells-A Qualitative Exploration of Expert Views.Stem cells translational medicine · 2023Article
- Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World.Pharmaceuticals (Basel, Switzerland) · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, the acceleration in the clinical use of mesenchymal stromal cells (MSCs) has been nothing short of spectacular. Perhaps most surprising is how little we know about the "MSC product." Although MSCs are being delivered to patients at an alarming rate, the regulatory requirements for MSC therapies (for example in terms of quality assurance and quality control) are nowhere near the expectations of traditional pharmaceuticals. That said, the standards that define a chemical compound or purified recombinant protein cannot be applied with the same stringency to a cell-based therapy. Biological processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge within even the most rigorously sorted clonal cell populations. With MSCs, perhaps more so than any other therapeutic cell, heterogeneity pervades at multiple levels, from the sample source to the single cell. The research and clinical communities collectively need to recognize and take steps to address this troublesome truth, to ensure that the promise of MSC-based therapies is fulfilled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.